Skip to main content
. 2017 Apr 24;292(24):10275–10287. doi: 10.1074/jbc.M116.770974

Figure 5.

Figure 5.

IL-1β induces C/EBPδ. A and B, HepG2 cells were treated with or without IL-1β (25 ng/ml) for the indicated time. Expression of the C/EBP family of proteins was examined by RT-qPCR analysis (A) with the level in the control cells prior to IL-1β treatment defined as 1. The data are presented as the mean ± S.E. (n = 3). *, p < 0.05 and **, p < 0.01 versus cells treated without IL-1β at the respective time point. B, C/EBPδ was examined by Western blot analysis with β-actin as the loading control. C and D, HepG2 cells were pretreated with or without BAY 11-7085 (5 μm, BAY) followed by treatment with or without IL-1β (10 ng/ml). C/EBPδ expression was examined by RT-qPCR analysis (C). The levels in the control cells treated without BAY 11-7085 were defined as 1. The data are presented as the mean ± S.E. (n = 3). **, p < 0.01 versus cells treated with the respective inhibitor (vehicle or BAY 11-7085) without IL-1β treatment. †, p < 0.05 and ††, p < 0.01 versus cells with corresponding IL-1β treatments in the absence of BAY 11-7085. D, C/EBPδ and β-actin expression was examined by Western blot analysis.